David I. Chemerow
Known title: DirectorCIK: 0001193743
Associated companies
Transaction History
| AIM | ▼ Sell | Other | 25,000 | $0 | 3/12/2026 | View on chart |
| AIM | ▲ Buy | Grant | 2,800 | $3K | 2/5/2026 | View on chart |
| AIM | ▲ Buy | Grant | 44,899 | $5K | 3/14/2025 | View on chart |
| AIM | ▲ Buy | Grant | 19,290 | $3K | 2/28/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress
AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress. AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.